Literature DB >> 3342035

The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vitro.

M Gschwendt1, W Kittstein, F Marks.   

Abstract

Various biological effects induced by the tumor promoting phorbol ester TPA in mouse skin are comparably suppressed by the immunologically inactive cyclosporine H (CsH) and by the strongly immunosuppressive cyclosporine A (CsA). These effects inhibited include the development of edema, stimulation of alkaline phosphatase activity, DNA and protein synthesis, as well as tumor promotion. Furthermore, CsH, like CsA, inhibits the Ca2+/calmodulin-dependent phosphorylation of the elongation factor 2 (EF-2) in vitro and the TPA-induced increases in the amount of EF-2 in vivo. Similar observations were made using the weak immunosuppressant CsD. We conclude from these results that the ability of cyclosporines to act as immunosuppressants and their ability to inhibit TPA-effects are based on two different mechanisms of action. Inhibition of TPA-effects may involve suppression of calmodulin-dependent processes, such as augmentation and phosphorylation of EF-2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342035     DOI: 10.1016/0006-291x(88)90428-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Cyclosporin A inhibits phorbol ester-induced activation of superoxide production in resident mouse peritoneal macrophages.

Authors:  M D Chiara; F Bedoya; F Sobrino
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

2.  Effects of topical cyclosporin A on guinea-pig toxic contact dermatitis.

Authors:  M Yokoo; D Oka; S Nakagawa
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

Review 4.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 5.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

Review 6.  From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.

Authors:  Charles V Clevenger; Jiamao Zheng; Elizabeth M Jablonski; Traci L Galbaugh; Feng Fang
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

7.  In vitro screening of 65 mycotoxins for insecticidal potential.

Authors:  Mieczysława Irena Boguś; Anna Katarzyna Wrońska; Agata Kaczmarek; Martyna Boguś-Sobocińska
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.